(Q39515657)

12 September 2017

title

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells (English)

1 reference

12 September 2017

1 reference

1 reference

Elvira Favoino

2

0 references

author name string

Ling Yu

1

1 reference

12 September 2017

Yangyang Wang

3

1 reference

12 September 2017

Yang Ma

4

1 reference

12 September 2017

Xiaojuan Deng

5

1 reference

12 September 2017

Xinhui Wang

6

1 reference

12 September 2017

language of work or name

1 reference

1 August 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

50

1 reference

12 September 2017

issue

2-3

1 reference

12 September 2017

page(s)

294-302

1 reference

Epidemiology of invasive cutaneous melanoma

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Radiation therapy of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

World Health Organization experience in the treatment of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

BRAF, a target in melanoma: implications for solid tumor drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Targeting multiple kinase pathways: a change in paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

CSPG4 in cancer: multiple roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Phosphorylated 4E-BP1 is associated with poor survival in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8232-Z

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

21 January 2018

1 reference

12 December 2020

Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells

1 reference

12 December 2020

Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR,DP monoclonal antibody CR11-462

1 reference

12 December 2020

BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC.

1 reference

12 December 2020

10.1007/S12026-011-8232-Z

Identifiers

DOI

1 reference

12 September 2017

1 reference